Raw counts of CRISPR/Cas9 activation screens using the Calabrese library upon regorafenib or DMSO treatment in GS-9, LN229, LN18, LNZ308, and T98G glioma cell lines
Following nearly five decades with few approved therapies for acute myeloid leukemia (AML), the last three years have brought stellar progress with the U.S. Food and Drug Administration approving a nu
